CDKN2B

Across TCGA pan-cancer cohorts, CDKN2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDKN2B data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CDKN2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDKN2B expression acts as an unfavorable survival marker.

LUAD, UCEC, and LUSC are the cancer types where CDKN2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.173	0.711	<.001	33	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	All	0.196	0.675	.049	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CDKN2B–LUAD (OS)

Open the LUAD breakdown →